{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T03:06:31Z","timestamp":1791083191642,"version":"4.1.0"},"reference-count":20,"publisher":"Oxford University Press (OUP)","issue":"9","license":[{"start":{"date-parts":[[2018,6,15]],"date-time":"2018-06-15T00:00:00Z","timestamp":1529020800000},"content-version":"vor","delay-in-days":1,"URL":"https:\/\/academic.oup.com\/journals\/pages\/about_us\/legal\/notices"}],"funder":[{"name":"RECLAIM 1 and 2","award":["NCT01499290"],"award-info":[{"award-number":["NCT01499290"]}]},{"name":"RECLAIM 3","award":["NCT01726023"],"award-info":[{"award-number":["NCT01726023"]}]},{"name":"REPRISE","award":["NCT01644643"],"award-info":[{"award-number":["NCT01644643"]}]},{"name":"RECAPTURE 1 and 2","award":["NCT01595438"],"award-info":[{"award-number":["NCT01595438"]}]},{"name":"RECAPTURE 1 and 2","award":["NCT01599806"],"award-info":[{"award-number":["NCT01599806"]}]},{"name":"REPROVE","award":["NCT01808092"],"award-info":[{"award-number":["NCT01808092"]}]},{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2018,9,1]]},"DOI":"10.1093\/jac\/dky204","type":"journal-article","created":{"date-parts":[[2018,5,14]],"date-time":"2018-05-14T07:07:12Z","timestamp":1526281632000},"page":"2519-2523","source":"Crossref","is-referenced-by-count":75,"title":["Clinical activity of ceftazidime\/avibactam against MDR Enterobacteriaceae and Pseudomonas aeruginosa: pooled data from the ceftazidime\/avibactam Phase III clinical trial programme"],"prefix":"10.1093","volume":"73","author":[{"given":"Gregory G","family":"Stone","sequence":"first","affiliation":[{"name":"AstraZeneca Pharmaceuticals, 35 Gatehouse Drive, Waltham, MA 02451, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Newell","sequence":"additional","affiliation":[{"name":"AstraZeneca Global Medicines Development, Alderley Park, Macclesfield, Cheshire SK10 4TG, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leanne B","family":"Gasink","sequence":"additional","affiliation":[{"name":"AstraZeneca, 1800 Concord Pike, Wilmington, DE 19803, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helen","family":"Broadhurst","sequence":"additional","affiliation":[{"name":"AstraZeneca Global Medicines Development, Alderley Park, Macclesfield, Cheshire SK10 4TG, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angela","family":"Wardman","sequence":"additional","affiliation":[{"name":"AstraZeneca Global Medicines Development, Alderley Park, Macclesfield, Cheshire SK10 4TG, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katrina","family":"Yates","sequence":"additional","affiliation":[{"name":"AstraZeneca Global Medicines Development, Alderley Park, Macclesfield, Cheshire SK10 4TG, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhangjing","family":"Chen","sequence":"additional","affiliation":[{"name":"AstraZeneca, 199 Liangjing Road, Shanghai 201203, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Song","sequence":"additional","affiliation":[{"name":"AstraZeneca, 199 Liangjing Road, Shanghai 201203, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5934-5877","authenticated-orcid":false,"given":"Joseph W","family":"Chow","sequence":"additional","affiliation":[{"name":"AstraZeneca, 1800 Concord Pike, Wilmington, DE 19803, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2018,6,14]]},"reference":[{"key":"key\n\t\t\t\t20180823025359_dky204-B1","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1097\/MCP.0b013e32835f27be","article-title":"Hospital-acquired pneumonia and ventilator-associated pneumonia: recent advances in epidemiology and management","volume":"19","author":"Barbier","year":"2013","journal-title":"Curr Opin Pulm Med"},{"key":"key\n\t\t\t\t20180823025359_dky204-B2","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1089\/sur.2013.262","article-title":"The challenge of antimicrobial resistance in managing intra-abdominal infections","volume":"16","author":"Sartelli","year":"2015","journal-title":"Surg Infect (Larchmt)"},{"key":"key\n\t\t\t\t20180823025359_dky204-B3","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1038\/nrurol.2015.199","article-title":"The emerging threat of multidrug-resistant Gram-negative bacteria in urology","volume":"12","author":"Zowawi","year":"2015","journal-title":"Nat Rev Urol"},{"key":"key\n\t\t\t\t20180823025359_dky204-B4","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1111\/j.1469-0691.2012.03821.x","article-title":"Rapid evolution and spread of carbapenemases among Enterobacteriaceae in Europe","volume":"18","author":"Cant\u00f3n","year":"2012","journal-title":"Clin Microbiol Infect"},{"key":"key\n\t\t\t\t20180823025359_dky204-B5","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1179\/1973947813Y.0000000145","article-title":"Avibactam reverts the ceftazidime MIC90 of European Gram-negative bacterial clinical isolates to the epidemiological cut-off value","volume":"26","author":"Flamm","year":"2014","journal-title":"J Chemother"},{"key":"key\n\t\t\t\t20180823025359_dky204-B6","doi-asserted-by":"crossref","first-page":"1789","DOI":"10.1128\/AAC.04191-14","article-title":"In vitro susceptibility of characterized \u03b2-lactamase-producing strains tested with avibactam combinations","volume":"59","author":"Li","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t20180823025359_dky204-B7","author":"Allergan"},{"key":"key\n\t\t\t\t20180823025359_dky204-B8","author":"Pfizer"},{"key":"key\n\t\t\t\t20180823025359_dky204-B9","doi-asserted-by":"crossref","first-page":"1380","DOI":"10.1093\/cid\/ciw133","article-title":"Efficacy and safety of ceftazidime-avibactam plus metronidazole versus meropenem in the treatment of complicated intra-abdominal infection: results from a randomized, controlled, double-blind, phase 3 program","volume":"62","author":"Mazuski","year":"2016","journal-title":"Clin Infect Dis"},{"key":"key\n\t\t\t\t20180823025359_dky204-B10","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1016\/j.ijantimicag.2017.01.010","article-title":"A randomised, double-blind, phase III study comparing the efficacy and safety of ceftazidime-avibactam plus metronidazole versus meropenem for complicated intra-abdominal infections in hospitalised adults in Asia","volume":"49","author":"Qin","year":"2017","journal-title":"Int J Antimicrob Agents"},{"key":"key\n\t\t\t\t20180823025359_dky204-B11","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1093\/cid\/ciw378","article-title":"Ceftazidime-avibactam versus doripenem for the treatment of complicated urinary tract infections, including acute pyelonephritis: RECAPTURE, a phase 3 randomized trial program","volume":"63","author":"Wagenlehner","year":"2016","journal-title":"Clin Infect Dis"},{"key":"key\n\t\t\t\t20180823025359_dky204-B12","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/S1473-3099(17)30747-8","article-title":"Ceftazidime-avibactam versus meropenem in nosocomial pneumonia, including ventilator-associated pneumonia (REPROVE): a randomised, double-blind, phase 3 non-inferiority trial","volume":"18","author":"Torres","year":"2018","journal-title":"Lancet Infect Dis"},{"key":"key\n\t\t\t\t20180823025359_dky204-B13","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1016\/S1473-3099(16)30004-4","article-title":"Ceftazidime-avibactam or best available therapy in patients with ceftazidime-resistant Enterobacteriaceae and Pseudomonas aeruginosa complicated urinary tract infections or complicated intra-abdominal infections (REPRISE): a randomised, pathogen-directed, phase 3 study","volume":"16","author":"Carmeli","year":"2016","journal-title":"Lancet Infect Dis"},{"key":"key\n\t\t\t\t20180823025359_dky204-B14","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1111\/j.1469-0691.2011.03570.x","article-title":"Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance","volume":"18","author":"Magiorakos","year":"2012","journal-title":"Clin Microbiol Infect"},{"key":"key\n\t\t\t\t20180823025359_dky204-B15","volume-title":"Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria That Grow Aerobically\u2014Tenth Edition: Approved Standard M07-A10","author":"Clinical and Laboratory Standards Institute","year":"2015"},{"key":"key\n\t\t\t\t20180823025359_dky204-B16","volume-title":"Performance Standards for Antimicrobial Susceptibility Testing: Twenty-Eighth Informational Supplement: M100-S28","author":"Clinical Laboratory Standards Institute","year":"2018"},{"key":"key\n\t\t\t\t20180823025359_dky204-B17","doi-asserted-by":"crossref","first-page":"e01045-17","DOI":"10.1128\/AAC.01045-17","article-title":"Antimicrobial activity of ceftazidime-avibactam tested against multidrug-resistant Enterobacteriaceae and Pseudomonas aeruginosa isolates from U.S. Medical Centers, 2013 to 2016","volume":"61","author":"Sader","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t20180823025359_dky204-B18","first-page":"eP435","volume-title":"Abstracts of the Twenty-fourth European Congress of Clinical Microbiology and Infectious Diseases, Barcelona, Spain, 2014","author":"Flamm"},{"key":"key\n\t\t\t\t20180823025359_dky204-B19","doi-asserted-by":"crossref","first-page":"3656","DOI":"10.1128\/AAC.05024-14","article-title":"Ceftazidime-avibactam activity against multidrug-resistant Pseudomonas aeruginosa isolated in U.S. medical centers in 2012 and 2013","volume":"59","author":"Sader","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t20180823025359_dky204-B20","first-page":"S130","article-title":"\u03b2-Lactamase characterization of baseline Pseudomonas aeruginosa (PSA) from five ceftazidime-avibactam (CAZ-AVI) Phase 3 clinical trials","volume":"4","author":"Mendes","year":"2017","journal-title":"Open Forum Infect Dis"}],"container-title":["Journal of Antimicrobial Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/jac\/article-pdf\/73\/9\/2519\/25523303\/dky204.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,10,17]],"date-time":"2019-10-17T20:41:00Z","timestamp":1571344860000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jac\/article\/73\/9\/2519\/5038107"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,6,14]]},"references-count":20,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2018,6,14]]},"published-print":{"date-parts":[[2018,9,1]]}},"URL":"https:\/\/doi.org\/10.1093\/jac\/dky204","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.733464902.793555355","asserted-by":"object"}]},"ISSN":["0305-7453","1460-2091"],"issn-type":[{"value":"0305-7453","type":"print"},{"value":"1460-2091","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2018,9]]},"published":{"date-parts":[[2018,6,14]]}}}